Xiyue Jing1, Chongbiao Huang2, Hongyu Zhou1, Changping Li1, Linlin Fan3, Jiageng Chen1, Guan Zhang1, Yuanyuan Liu1, Zhuang Cui1, Daliang Qi4, Jun Ma1. 1. Department of Health Statistics, College of Public Health, Tianjin Medical University No. 22 Qixiangtai Road, Heping District, Tianjin 300070, P. R. China. 2. National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, P. R. China. 3. Department of Health Statistics, College of Public Health, Tianjin Medical University No. 22 Qixiangtai Road, Heping District, Tianjin 300070, P. R. China ; Tianjin First Center Hospital 24 Fukang Road, Nankai District, Tianjin 300192, P. R. China. 4. VIP Oncology Ward, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, P. R. China.
Abstract
OBJECTIVE: C-reactive protein (CRP) has been reported, with controversy, to be associated with poor survival of patients with non-small cell lung cancer (NSCLC). This meta-analysis aimed to evaluate the prognostic role of CRP in NSCLC. METHODS: We searched PubMed, EMBASE and CNKI databases for published studies that evaluated the prognostic role of CRP in NSCLC up to March 1, 2014. The data were analyzed using STATA software (Version 12.0; Stata Corporation). Hazard ratios (HRs) with a 95% CI and 5-year survival rates were calculated to evaluate the relationships between CRP levels and the prognosis of NSCLC patients. RESULTS: Eight studies were included, totaling 1668 NSCLC patients. The results revealed that elevated CRP values might predict poor 5-year overall survival rates (RR=2.15, 95% CI: 1.78-2.59) and poor 5-year disease-specific survival rates (RR=2.12, 95% CI: 1.56-2.88). The pooled HR between stage I/II and stage III/IV patients was 0.98 (95% CI: 0.26-3.63, P=0.976), which indicated that the difference between the survival rates of the patients with elevated CRP and those with undetectable CRP was not significant. In our survival analysis, the results of Egger's testing did not demonstrate evidence of publication bias (P=0.099). CONCLUSION: Elevated CRP level is relevant to poorer survival of NSCLC patients and might be used as a prognostic biomarker for NSCLC.
OBJECTIVE:C-reactive protein (CRP) has been reported, with controversy, to be associated with poor survival of patients with non-small cell lung cancer (NSCLC). This meta-analysis aimed to evaluate the prognostic role of CRP in NSCLC. METHODS: We searched PubMed, EMBASE and CNKI databases for published studies that evaluated the prognostic role of CRP in NSCLC up to March 1, 2014. The data were analyzed using STATA software (Version 12.0; Stata Corporation). Hazard ratios (HRs) with a 95% CI and 5-year survival rates were calculated to evaluate the relationships between CRP levels and the prognosis of NSCLCpatients. RESULTS: Eight studies were included, totaling 1668 NSCLCpatients. The results revealed that elevated CRP values might predict poor 5-year overall survival rates (RR=2.15, 95% CI: 1.78-2.59) and poor 5-year disease-specific survival rates (RR=2.12, 95% CI: 1.56-2.88). The pooled HR between stage I/II and stage III/IV patients was 0.98 (95% CI: 0.26-3.63, P=0.976), which indicated that the difference between the survival rates of the patients with elevated CRP and those with undetectable CRP was not significant. In our survival analysis, the results of Egger's testing did not demonstrate evidence of publication bias (P=0.099). CONCLUSION: Elevated CRP level is relevant to poorer survival of NSCLCpatients and might be used as a prognostic biomarker for NSCLC.
Authors: D Salmerón; M D Chirlaque; M Isabel Izarzugaza; M J Sánchez; R Marcos-Gragera; E Ardanaz; J Galceran; A Mateos; C Navarro Journal: Respir Med Date: 2012-06-29 Impact factor: 3.415
Authors: Thomas Klikovits; Paul Stockhammer; Viktoria Laszlo; Yawen Dong; Mir Alireza Hoda; Bahil Ghanim; Isabelle Opitz; Thomas Frauenfelder; Thi Dan Linh Nguyen-Kim; Walter Weder; Walter Berger; Michael Grusch; Clemens Aigner; Walter Klepetko; Balazs Dome; Ferenc Renyi-Vamos; Rudolf Oehler; Balazs Hegedus Journal: Sci Rep Date: 2017-11-28 Impact factor: 4.379
Authors: Nigar Dirican; Ahmet Dirican; Ceyda Anar; Sule Atalay; Onder Ozturk; Ahmet Bircan; Ahmet Akkaya; Munire Cakir Journal: Asian Pac J Cancer Prev Date: 2016-12-01